Our findings warrant the future investigation of ATR inhibitors in clinical trials, such as the currently undergoing phase I/II trial of BAY 1895344 (Elimusertib) in relapsed PAX3-FOXO1-expressing rhabdomyosarcoma (NCT05071209). Here, PAX3 is linked to rhabdomyosarcoma.